How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Novel inhibitors targeting colonization and virulence of gastrointestinal pathogens

Organization name

Clinic Invent


Diseases caused by toxin-producing pathogens are a worldwide health threat. Shiga Toxin (Stx)-producing Escherichia coli (STEC) and in particular human pathogenic enterohemorrhagic E. coli (EHEC) cause severe intestinal infections such as hemorrhagic colitis and lifeendangering extraintestinal complications like the hemolytic-uremic syndrome (HUS). Stx, by definition a lectin with certain carbohydratebinding specificity, belongs to the group of AB5 toxins and represents the major virulence factor of EHEC. So far, no causal treatment of EHEC infections is available. The lack of causal therapy options became evident during large EHEC outbreaks in the past, which were caused by EHEC O157:H7 and O104:H4 serotypes.

Technology offered:

The present technology relates to methods of preparing a number of pectic oligosaccharides (POS) and neoglycolipids (neoGLs) that have the potential to inhibit binding of Stx to its genuine receptors on the cell surface of a human or animal.

Besides treatment of EHEC-caused intestinal diseases and extraintestinal or systemic complications, UPEC (uropathogenic E. coli)-triggered urinary tract infections and the edema disease of pigs provide further clinical applications of the produced POS and neoGLs as well.

In addition, there are numerous other implementations to benefit from inhibitory effects of POS and POS-derivatives against toxins re-leased by bacteria into the environment and for adhesin-bearing pathogens in numerous biological habitats. Such compounds might be useful for example as biological adsorbers of toxins or bacteria in filter systems for drinking water purification, swimming pools or spas, for municipal wastewater treatment and for detox-ification of feces in slaughterhouses as well as for air filters of all kinds. Further applications are easily conceivable wherever bacteria-released toxins or adhesive pathogenic bacteria occur.

Advantages of the technology:

  • low price of the raw material
  • available virtually in unlimited amounts
  • nonhazardous for humans and animals
  • high "consumer acceptance"

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries